


## **Enabling Informed Decisions in Breast Cancer through Information Technologies**

- Το Ευρωπαϊκό έργο DESIREE θα παράξει ένα πρότυπο **σύστημα υποβοήθησης λήψης αποφάσεων** για χρήση στις Ογκολογικές Μονάδες Μαστού (BUs).
- Το έργο DESIREE θα υποβοηθήσει τη διαδικασία με την οποία οι επαγγελματίες υγείας αποφασίζουν για τη βέλτιστη θεραπεία ασθενών με πρώιμο καρκίνο μαστού, αξιοποιώντας καινοτόμες τεχνολογίες και αλγόριθμους υποβοήθησης λήψης απόφασης με βάση τις εκάστοτε κλινικές οδηγίες, ανάκτηση γνώσης και λογική βάση περιπτώσεων (advanced clinical decision support systems, knowledge discovery, case based reasoning), εργαλεία ανάλυσης εικόνας και χαρακτηρισμού όγκου, καθώς και προγνωστική μοντελοποίηση με 3D ανασύσταση (image-based breast and tumour characterization tools, predictive modeling for 3D breast reconstruction).
- Παρακολουθήστε το demo video από την τρέχουσα έκδοση του υπό δημιουργία συστήματος. Δυνατότητα και για LIVE κατ'ιδίαν demo, στις **29 & 30 Ιανουαρίου 2018**, κατά τη διάρκεια της συνάντησης εργασίας του Ευρωπαϊκού έργου DESIREE στην Αθήνα (**Ξενοδοχείο Τιτάνια**): [https://www.youtube.com/watch?v=nXΕopw7\\_lv4](https://www.youtube.com/watch?v=nXΕopw7_lv4)




- Η Ελληνική εταιρεία Medical Innovation and Technology συμμετέχει στο έργο DESIREE ως τεχνολογικός εταίρος. Το DESIREE χρηματοδοτείται από την Ευρωπαϊκή Επιτροπή, στο πλαίσιο του προγράμματος "Ορίζοντας 2020" για την έρευνα και την καινοτομία (GA No 690238).
- Περισσότερες πληροφορίες για το έργο DESIREE ακολουθούν παρακάτω στα αγγλικά καθώς και στα επίσημα κανάλια επικοινωνίας: [Website](#) | [Blog](#) | [Twitter](#) | [YouTube](#) [Newsletter](#) & [desiree-contact@vicomtech.org](mailto:desiree-contact@vicomtech.org), [athina@medicalinnovation.gr](mailto:athina@medicalinnovation.gr) & 6947 638362 (κα. Αθηνά Παπαθεοδώρου)



## Enabling Informed Decisions in Breast Cancer through Information Technologies

- The DESIREE project will provide a decision support system for use in Breast Units to apply specific therapies for each patient depending on the diagnosis.
- DESIREE will help breast cancer clinicians in their decision making process, with technology that includes advanced clinical decision support systems (based on formalized clinical guidelines, knowledge discovery, and case based reasoning), image-based breast and tumour characterization tools and predictive modeling for 3D breast reconstruction.
- Watch the newly released **demo video** for a sneak preview:  
[https://www.youtube.com/watch?v=nXEopw7\\_lv4](https://www.youtube.com/watch?v=nXEopw7_lv4)



- LIVE demo is available on request, during **29-30 January 2018**, during the **European H2020 DESIREE Project team meeting** in Athens, Titania Hotel (Panepistimiou 52, Athens).

**Athens, 29<sup>th</sup> January 2018.** Breast cancer is the most common tumour in European women. A large volume of breast cancer related data has accumulated as a result of diagnostic tests and treatments. These data contain valuable information which, if utilised properly and sufficiently, may support early diagnosis and better treatment of new patients. Due to the fast introduction of digital technologies in medicine in recent years, the available information has outgrown the analytical capacity, a challenge that can be addressed by computer vision based tools.

An EU Horizon 2020 funded project, *Decision Support and Information Management System for Breast Cancer (DESIREE)*, undertaken by an international consortium of companies, research centres, universities and hospitals coordinated by the Spanish Vicomtech and with the participation of the Greek SME Medical Innovation and Technology, will address this challenge. This will be done by developing



technologies that bring together all information and process it accurately, smartly and in a multidisciplinary fashion. The technologies will be integrated into a web-based system that accelerates the management of all available information of breast cancer cases, provides a more customised and holistic view of the patient, obtains new evidence based on accumulated and collaborative experiences, and provides agile, intuitive and visual tools for clinical decision support. In particular, the DESIREE project aims at developing tools for the prognosis and evolution of the clinical treatment based on images, allowing to predict the evolution of the breast cancer through non-invasive techniques (mammography, magnetic resonance, digital tomosynthesis, etc.). Moreover, an innovative technology will be developed simulating the breast surgery process based on the physiological model, which will predict the aesthetic result of the surgery and will have important implications in the interaction of the doctor with the patient and in the decision making of the patient.

The project intends to be an international benchmark in the efficient use of medical digital data of any kind with the aim of improving the clinical breast cancer practice.

On 29<sup>th</sup> and 30<sup>th</sup> January the project partners are gathering in Athens, at Titania Hotel, as part of the periodic plenary working meetings. Medical Innovation and Technology, the Greek technological SME, is now taking over the local organizer & facilitator role, hoping that the team will make the most of the city's ancient spirit to gain inspiration, insight, wisdom and enthusiasm! This will be the first meeting of the New Year, but also the first after the recent Project Review, which set the scene for an ambitious second half in the project lifetime!

### **The multidisciplinary consortium**

In order to optimise the value of the DESIREE project, all the experts of the value chain for the development and the validation are involved in the project. The DESIREE consortium, coordinated by Vicomtech, is constituted by 11 participants from 6 countries who gather all the necessary background and expertise to achieve the ambitious objectives of the project. The consortium, coordinated by the Spanish Vicomtech, includes ERESA, Sistemas Genómicos and Onkologikoa from Spain, Ulster University from North Ireland, the German ARIVIS, INSERM-LIMICS and Assistance publique – Hôpitaux de Paris (AP-HP) from France, Medical Innovation and Technology from Greece and Houston Methodist Hospital from the USA.

This research and innovation project started in February 2016 and has a duration of 36 months. DESIREE has received funding from the **European Union's Horizon 2020 research and innovation programme** under grant agreement No 690238.

### **More on DESIREE Project:**

[Website](#) | [Blog](#) | [Twitter](#) | [YouTube](#)

Or read out latest [Newsletter](#)

**Contact:** [desiree-contact@vicomtech.org](mailto:desiree-contact@vicomtech.org), [athina@medicalinnovation.gr](mailto:athina@medicalinnovation.gr)